Glucagon-like peptide-1(1-37) can enhance blood glucose homeostasis in mice

Regulatory Peptides

Volumn 178, Issue 1-3, 2012, Pages 1-5

  Zhao, Lifen ^a   Ye, Haifeng ^b   Li, Dongqing ^a   Lao, Xun ^a   Li, Juan ^a   Wang, Zhenghua ^a   Xiao, Lei ^a   Wu, Zirong ^a   Huang, Jing ^a  

^a EAST CHINA NORMAL UNIVERSITY   (China)

^b ETH ZURICH   (Switzerland)

Author keywords

Blood glucose homeostasis; Exendin(9 39); GLP 1(1 37); Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1[1-37]; GLUCOSE; LUCIFERASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; EMBRYO; FEMALE; GENE EXPRESSION REGULATION; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANIMALS; AREA UNDER CURVE; BLOOD GLUCOSE; DRUG STABILITY; ESCHERICHIA COLI; FEMALE; GENES, REPORTER; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; HEK293 CELLS; HOMEOSTASIS; HUMANS; HYPOGLYCEMIC AGENTS; LUCIFERASES; MICE; PEPTIDE FRAGMENTS; RECEPTORS, GLUCAGON; RECOMBINANT PROTEINS;

MUS;

EID: 84865377926     PISSN: 01670115     EISSN: 18731686     Source Type: Journal    
DOI: 10.1016/j.regpep.2012.06.010     Document Type: Article

References (23)

1. Li Y., Hansotia T., Yusta B., Ris F., Halban P.A., Drucker D.J. Glucagon-like peptide-1 receptor signaling modulates β cell apoptosis. J Biol Chem 2003, 278:471-478.
2. Baggio L.L., Drucker D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007, 132:2131-2157.
3. Gautier J.F., Choukem S.P., Girard J. Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes. Diabetes Metab 2008, 34:S65-S72.
4. Qualmann C., Nauck M.A., Holst J.J., Ørskov C., Creutzfeldt W. Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7-36 amide] in the fasting state in healthy subjects. Acta Diabetol 1995, 32:13-16.
5. Kjems L.L., Holst J.J., Vølund A., Madsbad S. The influence of GLP-1 on glucose-stimulated insulin secretion. Diabetes 2003, 52:380-386.
6. Friedrichsen B.N., Neubauer N., Lee Y.C., Gram V.K., Blume N., Petersen J.S., Nielsen J.H., Møldrup A. Stimulation of pancreatic β-cell replication by incretins involves transcriptional induction of cyclin D1 via multiple signalling pathways. J Endocrinol 2006, 188:481-492.
7. Schirra J., Göke B. The physiological role of GLP-1 in human: incretin, ileal brake or more?. Regul Pept 2005, 128:109-115.
8. Elahi D., Egan J.M., Shannon R.P., Meneilly G.S., Khatri A., Habener J.F., Andersen D.K. GLP-1 (9-36) amide, cleavage product of GLP-1 (7-36) amide, is a glucoregulatory peptide. Obesity 2008, 16:1501-1509.
9. Juhl C.B., Hollingdal M., Sturis J., Jakobsen G., Agersø H., Veldhuis J., Pørksen N., Schmitz O. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes 2002, 51:424-429.
10. Salehi M., Aulinger B.A., D'Alessio D.A. Targeting β-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins. Endocr Rev 2008, 29:367-379.
11. Orskov C., Rabenhøj L., Wettergren A., Kofod H., Holst J.J. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 1994, 43:535-539.
12. Rouillé Y., Martin S., Steiner D.F. Differential processing of proglucagon by the subtilisin-like prohormone convertases PC2 and PC3 to generate either glucagon or glucagon-like peptide. J Biol Chem 1995, 270:26488-26496.
13. Marx N., Burgmaier M., Heinz P., Ostertag M., Hausauer A., Bach H., Durst R., Hombach V., Walcher D. Glucagon-like peptide-1(1-37) inhibits chemokine-induced migration of human CD4-positive lymphocytes. Cell Mol Life Sci 2010, 67:3549-3555.
14. Suzuki A., Nakauchi H., Taniguchi H. Glucagon-like peptide 1 (1-37) converts intestinal epithelial cells into insulin-producing cells. Proc Natl Acad Sci U S A 2003, 100:5034-5039.
15. Wu Y.-L., Huang J., Xu J., Liu J., Feng Z., Wang Y., Lai Y., Wu Z.-R. Addition of a cysteine to glucagon-like peptide-1 (GLP-1) conjugates GLP-1 to albumin in serum and prolongs GLP-1 action in vivo. Regul Pept 2010, 164:83-89.
16. Ritzel U., Leonhardt U., Ottleben M., Ruhmann A., Eckart K., Spiess J., Ramadori G. A synthetic glucagon-like peptide-1 analog with improved plasma stability. J Endocrinol 1998, 159:93-102.
17. George S.E., Bungay P.J., Naylor L.H. Evaluation of a CRE-directed luciferase reporter gene assay as an alternative to measuring cAMP accumulation. J Biomol Screen 1997, 2:235-240.
18. Deacon C.F., Johnsen A.H., Holst J.J. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995, 80:952-957.
19. Kieffer T.J., McIntosh C.H., Pederson R.A. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995, 136:3585-3596.
20. Green B.D., Liu H.K., McCluskey J.T., Duffy N.A., O'Harte F.P.M., McClenaghan N.H., Flatt P.R. Function of a long-term, GLP-1-treated, insulin-secreting cell line is improved by preventing DPP IV-mediated degradation of GLP-1. Diabetes Obes Metab 2005, 7:563-569.
21. Ugleholdt R., Zhu X., Deacon C.F., Ørskov C., Steiner D.F., Holst J.J. Impaired intestinal proglucagon processing in mice lacking prohormone convertase 1. Endocrinology 2004, 145:1349-1355.
22. Rouillé Y., Kantengwa S., Irminger J.-C., Halban P.A. Role of the prohormone convertase PC3 in the processing of proglucagon to glucagon-like peptide 1. J Biol Chem 1997, 272:32810-32816.
23. Stridsberg M., Eriksson B., Janson E.T. Measurements of secretogranins II, III, V and proconvertases 1/3 and 2 in plasma from patients with neuroendocrine tumours. Regul Pept 2008, 148:95-98.